

HR 3536

To require persons who undertake Federally funded research and development of drugs to enter into reasonable pricing agreements with the Secretary of Health and Human Services.

Congress: 115 (2017–2019, Ended)

Chamber: House

Policy Area: Health

Introduced: Jul 28, 2017

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Aug 4, 2017)

Official Text: <https://www.congress.gov/bill/115th-congress/house-bill/3536>

Sponsor

Name: Rep. DeFazio, Peter A. [D-OR-4]

Party: Democratic • **State:** OR • **Chamber:** House

Cosponsors (7 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Conyers, John, Jr. [D-MI-13]	D · MI		Sep 5, 2017
Rep. Cummings, Elijah E. [D-MD-7]	D · MD		Sep 5, 2017
Rep. Kaptur, Marcy [D-OH-9]	D · OH		Sep 5, 2017
Rep. Schakowsky, Janice D. [D-IL-9]	D · IL		Sep 5, 2017
Rep. Grijalva, Raúl M. [D-AZ-3]	D · AZ		Sep 7, 2017
Rep. Slaughter, Louise McIntosh [D-NY-25]	D · NY		Nov 8, 2017
Rep. Khanna, Ro [D-CA-17]	D · CA		Jul 11, 2018

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Aug 4, 2017

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
115 S 1681	Identical bill	Jul 31, 2017: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary (as of Jul 28, 2017)

This bill prohibits federal agencies and nonprofit entities that conduct federally funded health care research from providing a patent for a drug based on such research until the entity receiving the patent enters into a reasonable pricing agreement with the Department of Health and Human Services.

Actions Timeline

- **Aug 4, 2017:** Referred to the Subcommittee on Health.
- **Jul 28, 2017:** Introduced in House
- **Jul 28, 2017:** Referred to the House Committee on Energy and Commerce.